Now showing items 1-1 of 1

    • Nintedanib in ovarian cancer. 

      Khalique, S; Banerjee, S (2017-09)
      INTRODUCTION: Advanced ovarian cancer remains an unmet clinical need. Angiogenesis is considered a therapeutic target in ovarian cancer, with bevacizumab, a monoclonal antibody against VEGF, being the first drug to show a ...